Biograph hi rez 16

All patients in our training cohort were scanned using the same scanner (Biograph HI-REZ 16; Siemens Healthcare, Henkestr, Germany), following the criteria of the uniform protocols for imaging in clinical trials (UPICT) (Graham et al., 2015 (link)). Supplementary File S1 describing the details of the imaging protocol was provided. All images were evaluated using a commercial medical image-processing workstation (uWS-MI, United Imaging Healthcare, Shanghai, China). Two experienced nuclear medicine physicians (TT S & YL J) who were blinded to the patients’ clinical information independently analyzed the PET/CT images, resolving disagreements through consensus. Metabolic parameters including SULmax, SULpeak, SULmean, MTV in mL, and TLG were recorded on a lesion basis. Additionally, thoracic CECT images were reviewed by two board-certified radiologists (H Y & XC Z) who were blinded to the PET/CT study.

Image acquisition was performed using a whole-body PET/CT scanner (Biograph HI-REZ 16, Siemens Medical Solution). The equipment detail information was summarized in Supplementary Materials 2. Blood glucose levels (mmol/l) were measured prior to the ¹⁸F-FDG injection. Blood glucose levels should not be higher than 7 mmol/l; therefore, any patient with a blood glucose level above 7 mmol/l was rescheduled [17 –19 (link)]. All patients were implanted with 20 G indwelling intravenous catheters (Jierui Medical Product), followed by ¹⁸F-FDG manual administration with 5.55 MBq/kg. Patients were then instructed to lie on the bed as calmly as possible. Imaging was started 60 min after ¹⁸F-FDG injection. Detailed scanning and data reconstruction parameters were listed in Supplementary Materials 3.